Alliance Pharma Reports Steady 2024 Results Amidst Acquisition and AIM Delisting Plans

In the ever-evolving landscape of UK healthcare stocks, Alliance Pharma’s 2024 results read like a thriller novel with plot twists, strategic pivots, and a climactic takeover. Let’s dissect what’s really going on beneath the surface of these numbers-and why every investor should care.

A Year of Two Halves: Steady Performance Meets Structural Shakeups

Alliance Pharma’s 2024 could be summarised as “business as usual” with a side of corporate fireworks. Here’s the headline act:

• Revenue: £180.3m (down 1% YoY), but gross profit edged up 4% to £109.3m thanks to savvy product mix changes
• Cash is King: Free cash flow surged 37% to £29.1m, while net debt plummeted 34% to £60.1m
• Portfolio Pruning: Ditched 14 underperforming brands (8 sold, 6 discontinued) – surgical precision in action

But let’s not mistake “steady” for “stagnant”. Behind these numbers lies a company mid-metamorphosis.

Consumer Healthcare: The Good, The Bad, and The Scalp Care

Alliance’s consumer division showed why diversification matters:

• Winners: Kelo-Cote (scar care) grew 6% to £65.4m, MacuShield (eye health) up 11% to £10.2m
• Challenges: Nizoral (anti-dandruff) fell 21% to £16.4m due to distributor timing quirks

Meanwhile, prescription medicines quietly delivered an 8% revenue boost, proving that boring can be beautiful in pharma portfolios.

The Elephant in the Boardroom: DBAY’s Takeover and AIM Exit

The real blockbuster? January’s recommended £362m cash offer from majority shareholder DBAY. Key implications:

• 92% of voting shareholders said “yes” – hardly a hostile takeover
• AIM delisting expected by mid-2025 – end of an era for public market investors
• Strategic rationale: Private ownership could accelerate consumer healthcare focus without quarterly reporting constraints

As CEO Nick Sedgwick diplomatically puts it: “We’re bringing the consumer closer to the heart of the business.” Translation? Expect more Amazon-friendly launches and fewer legacy pharma hangovers.

Management Makeover: New Faces, Faster Pace

Alliance isn’t just changing owners-it’s rebuilding its C-suite from the ground up:

• Executive Committee expanded from 5 to 12 members
• 58% female representation vs 20% previously – diversity drive in action
• New roles including Chief Transformation Officer and Chief Supply Officer

This isn’t just corporate window dressing. The company’s shifting from a “prescription mindset” to consumer-first agility-a cultural revolution disguised as a reorg.

Sustainability & Scandal Survival

Beyond financials, Alliance scored key non-financial wins:

• 60% reduction in Scope 1-2 emissions since 2018 – on track for 2030 net zero
• Won CMA appeal (saving £7.9m provision) – legal drama averted
• Re-certified as Great Place to Work in 4 countries – crucial for talent retention

For ESG-focused investors, this triple play matters almost as much as the balance sheet.

The Final Act: What Comes Next?

As Alliance prepares to exit public markets, three key questions remain:

1. Can private ownership unlock faster innovation? (Their R&D spend remains modest at £1-2m/year)
2. Will the consumer healthcare pivot deliver promised growth? (Q1 2025 reportedly on track)
3. What legacy does this leave for AIM investors? (A case study in mid-cap pharma transitions)

One thing’s certain – Alliance’s 2024 results aren’t just a financial report card. They’re the closing chapter of a public market story, and the prologue to a new private equity-backed adventure.